| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2015: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Outline of Final Research Achievements |
We performed X-ray crystallographic analysis of the crystals obtained from the purified sample of FsrC that was supplemented with GBAP (an agonist) or an antagonist. The analysis revealed that the crystals obtained did not contain FsrC but instead contain AcrB, an E coli membrane protein involved in multidrug efflux. There were two kinds of AcrB; one was the crystal of the know AcrB structure, whereas the other was the crystal of a new AcrB structure. The analysis of the latter crystal structure is in progress because this crystal structure is as an important target as the FsrC structure. In addition, we found that the expression level of FsrC-GFP fusion protein was improved by coexpressing some kind of protease inhibitor.
|
